Champions Oncology(CSBR)
$4.78+0.03 (+0.63%)
CSBR
Champions Oncology financials statements
$4.78
At close:+0.03 (+0.63%)
Want to see CSBR full AI Analyst Report?
Champions Oncology (CSBR) Ratios
143 Followers
Champions Oncology Ratios
CSBR's free cash flow for Q1 2027 was $-547.00K. For the 2027 fiscal year, CSBR's free cash flow was decreased by $-55.00K and operating cash flow was $-492.00K. See a summary of the company’s cash flow.
| Ratios | Apr 26 | Apr 25 | Apr 24 | Apr 23 | Apr 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.96 | 0.94 | 0.63 | 0.90 | 1.13 |
| Quick Ratio | 0.96 | 0.94 | 0.63 | 0.90 | 1.13 |
| Cash Ratio | 0.24 | 0.41 | 0.12 | 0.47 | 0.52 |
| Solvency Ratio | 0.01 | 0.22 | -0.19 | -0.07 | 0.11 |
| Operating Cash Flow Ratio | -0.22 | 0.31 | -0.28 | 0.18 | 0.37 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -3.70M | $ -6.20M | $ -14.40M | $ -10.22M | $ -6.62M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.17 | 0.19 | 0.28 | 0.25 | 0.27 |
| Debt-to-Equity Ratio | 1.15 | 1.62 | -3.90 | 1.85 | 1.04 |
| Debt-to-Capital Ratio | 0.53 | 0.62 | 1.34 | 0.65 | 0.51 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 6.85 | 8.57 | -13.73 | 7.40 | 3.89 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -192.18 | 0.00 | 123.38 |
| Interest Coverage Ratio | 0.00 | 0.00 | -247.18 | 0.00 | 25.29 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.33 | 0.45 | 0.55 | 0.64 | 0.72 |
| Net Debt to EBITDA | -0.80 | -0.59 | -0.89 | 0.73 | 0.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 48.00% | 50.15% | 41.38% | 45.18% | 51.88% |
| EBIT Margin | -1.56% | 8.12% | -14.52% | -9.78% | 1.19% |
| EBITDA Margin | 0.75% | 11.00% | -10.79% | -3.84% | 6.10% |
| Operating Profit Margin | -1.92% | 8.51% | -13.80% | -8.26% | 1.24% |
| Pretax Profit Margin | -1.56% | 8.12% | -14.57% | -9.78% | 1.19% |
| Net Profit Margin | -1.98% | 8.26% | -14.51% | -9.90% | 1.12% |
| Continuous Operations Profit Margin | -1.98% | 8.26% | -14.51% | -9.90% | 1.12% |
| Net Income Per EBT | 126.48% | 101.62% | 99.56% | 101.29% | 94.00% |
| EBT Per EBIT | 81.49% | 95.46% | 105.59% | 118.39% | 96.05% |
| Return on Assets (ROA) | -4.35% | 14.53% | -27.84% | -15.55% | 1.55% |
| Return on Equity (ROE) | -29.83% | 124.63% | 382.34% | -115.08% | 6.02% |
| Return on Capital Employed (ROCE) | -16.13% | 57.07% | -150.75% | -35.37% | 3.39% |
| Return on Invested Capital (ROIC) | -13.28% | 48.64% | -116.24% | -32.27% | 3.01% |
| Return on Tangible Assets | -4.41% | 14.69% | -28.20% | -15.70% | 1.56% |
| Earnings Yield | -1.43% | 4.81% | -11.07% | -8.11% | 0.54% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.51 | 5.07 | 5.27 | 6.72 | 5.16 |
| Payables Turnover | 4.48 | 6.68 | 5.07 | 5.54 | 8.24 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 8.23 | 6.02 | 4.19 | 3.71 | 3.20 |
| Asset Turnover | 2.20 | 1.76 | 1.92 | 1.57 | 1.39 |
| Working Capital Turnover Ratio | -54.34 | -12.13 | -9.86 | -1183.96 | 27.16 |
| Cash Conversion Cycle | -0.60 | 17.39 | -2.68 | -11.65 | 26.41 |
| Days of Sales Outstanding | 80.94 | 72.01 | 69.32 | 54.28 | 70.70 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 81.54 | 54.62 | 72.00 | 65.93 | 44.30 |
| Operating Cycle | 80.94 | 72.01 | 69.32 | 54.28 | 70.70 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.32 | 0.54 | -0.45 | 0.29 | 0.49 |
| Free Cash Flow Per Share | -0.36 | 0.51 | -0.51 | 0.08 | 0.31 |
| Dividend Paid and CapEx Coverage Ratio | -7.93 | 18.99 | -7.34 | 1.38 | 2.73 |
| Capital Expenditure Coverage Ratio | -7.93 | 18.99 | -7.34 | 1.38 | 2.73 |
| Operating Cash Flow Coverage Ratio | -0.99 | 1.21 | -0.83 | 0.46 | 0.69 |
| Operating Cash Flow to Sales Ratio | -0.08 | 0.13 | -0.12 | 0.07 | 0.13 |
| Free Cash Flow Yield | -6.11% | 7.16% | -10.61% | 1.65% | 4.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -74.50 | 21.03 | -9.03 | -12.34 | 184.95 |
| Price-to-Sales (P/S) Ratio | 1.39 | 1.72 | 1.31 | 1.22 | 2.06 |
| Price-to-Book (P/B) Ratio | 20.93 | 25.89 | -34.53 | 14.20 | 11.14 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -16.37 | 13.96 | -9.42 | 60.77 | 24.64 |
| Price-to-Operating Cash Flow Ratio | -18.43 | 13.22 | -10.71 | 16.64 | 15.60 |
| Price-to-Earnings Growth (PEG) Ratio | 0.60 | -0.13 | -0.23 | 0.01 | 3.67 |
| Enterprise Value Multiple | 183.22 | 15.00 | -13.03 | -31.07 | 33.98 |
| Enterprise Value | 82.08M | 93.99M | 70.52M | 64.29M | 101.81M |
| EV to EBITDA | 183.22 | 15.00 | -13.03 | -31.07 | 33.98 |
| EV to Sales | 1.38 | 1.65 | 1.41 | 1.19 | 2.07 |
| EV to Free Cash Flow | -16.30 | 13.43 | -10.11 | 59.37 | 24.75 |
| EV to Operating Cash Flow | -18.35 | 12.73 | -11.49 | 16.26 | 15.67 |
| Tangible Book Value Per Share | 0.27 | 0.25 | -0.17 | 0.32 | 0.66 |
| Shareholders’ Equity Per Share | 0.28 | 0.28 | -0.14 | 0.34 | 0.69 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.26 | -0.02 | 0.00 | -0.01 | 0.06 |
| Revenue Per Share | 4.30 | 4.17 | 3.70 | 3.98 | 3.72 |
| Net Income Per Share | -0.08 | 0.34 | -0.54 | -0.39 | 0.04 |
| Tax Burden | 1.26 | 1.02 | 1.00 | 1.01 | 0.94 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.15 | 0.12 | 0.19 | 0.21 | 0.19 |
| SG&A to Revenue | 0.34 | 0.30 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 |
| Income Quality | 3.81 | 1.57 | 0.84 | -0.74 | 11.86 |
Currency in USD
